JNJ - J&J gene therapy shows encouraging action in vision loss disorder July, 17 2020 07:51 AM Johnson & Johnson Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical Companies reports positive six-month data from a Phase 1/2 clinical trial evaluating gene therapy AAV-RPGR in patients with X-linked retinitis pigmentosa, a group of inherited retinal disorders characterized by progressive vision loss.More news on: Johnson & Johnson, MeiraGTx Holdings plc, Healthcare stocks news, Stocks on the move, Read more ...